PET and restaging of malignant lymphoma including residual masses and relapse

[1]  V. Lowe,et al.  Assessment of Lymphoma Therapy Using (18)F-FDG PET. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  V. Diehl,et al.  Current treatment of follicular non-Hodgkin's lymphoma. , 2002, European journal of cancer.

[3]  P. Hoskin.  FDG PET in the management of lymphoma: a clinical perspective , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  U. Jaeger,et al.  Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation , 2002, Leukemia.

[5]  B Beuthien-Baumann,et al.  Prognostic value of positron emission tomography in the evaluation of post‐treatment residual mass in patients with Hodgkin's disease and non‐Hodgkin's lymphoma , 2001, British journal of haematology.

[6]  V. Diehl,et al.  Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. , 2001, Blood.

[7]  P. Dupont,et al.  Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.

[8]  L. Mortelmans,et al.  Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[9]  G. Segall.  FDG PET imaging in patients with lymphoma: a clinical perspective. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  F. Maul,et al.  Whole body positron emission tomography in the treatment of Hodgkin disease , 2001, Cancer.

[11]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Lammertsma,et al.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.

[13]  H. Heimpel,et al.  Role of whole body FDG-PET imaging in predicting relapse of malignant lymphoma in patients with residual masses after treatment , 1999 .

[14]  G. Jerusalem,et al.  Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.

[15]  A. Aisenberg.  Problems in Hodgkin's disease management. , 1999, Blood.

[16]  U. Cremerius,et al.  Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. , 1998, Nuclear medicine communications.

[17]  S. Reske,et al.  Vortäuschung eines mediastinalen Non-Hodgkin-Lymphomrezidivs durch diffuse Thymushyperplasie im 18F-FDG-PET , 1996 .

[18]  G. Canellos,et al.  Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  R. Buchert,et al.  18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin's lymphoma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  A. Padhani,et al.  Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? , 2000, European journal of cancer.

[21]  G. Jerusalem,et al.  Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.

[22]  J Kotzerke,et al.  Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. , 1999, Acta oncologica.

[23]  J. Neuerburg,et al.  Klinische Wertigkeit der FDG-PET zur Therapiekontrolle bei malignen Lymphomen – Ergebnisse einer retrospektiven Studie an 72 Patienten , 1999, Nuklearmedizin.

[24]  D. Bumann,et al.  Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.